SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wenk RE,Bhagavan BS,Levy R, et al. Ectopic ACTH, prostate oat cell carcinoma, and marked hypernatremia. Cancer. 1977; 40: 773778.
  • 2
    Amato RJ,Logothetis CJ,Hallinan R, et al. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992; 147: 804807.
  • 3
    Pearse AG,Takor T. Embryology of the diffuse neuroendocrine system and its relationship to the common peptides. Fed Proc. 1979; 38: 22882294.
  • 4
    Schron DS,Gipson T,Mendelsohn G. The histogenesis of small cell carcinoma of the prostate: an immunohistochemical study. Cancer. 1984; 53: 24782480.
  • 5
    Azzopardi JG,Evans DJ. Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol. 1971; 104: 247251.
  • 6
    Helpap B,Kollermann J,Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutic perspectives. Urol Int. 1999; 62: 133138.
  • 7
    Oesterling JE,Hauzeur CG,Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological, and immunohistochemical study of 27 patients. J Urol. 1992; 147: 804807.
  • 8
    Tetu B,Ro JY,Ayala AG, et al. Small cell carcinoma of the Prostate. Part I. A clinicopathologic study of 20 cases. Cancer. 1987; 59: 18031809.
  • 9
    Papandreou CN,Daliani DD,Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002; 20: 30723080.
  • 10
    Kaplan GL,Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 11
    Sato A,Ohigashi T,Oya M, et al. Clinicopathological features predicting nodal metastasis of testicular seminoma: results from 100 cases in a single institute. Urol Int. 2006; 77: 6468.
  • 12
    Eggener SE,Yossepowitch O,Pettus JA, et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006; 24: 31013106.
  • 13
    Tas F,Aydiner A,Demir C, et al. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small cell lung cancer. Am J Clin Oncol. 2001; 24: 376378.
  • 14
    Cengiz O,Kocer B,Surmeli S, et al. Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monit. 2006; 12: 240247.
  • 15
    Asmis TR,Reaume MN,Dahrouge S, et al. Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at the Ottawa Hospital Regional Cancer Center. BJU Int. 2006; 97: 711715.
  • 16
    Evans CP,Busby JE,Kung HJ, et al. Neuroendocrine differentiation contributes to prostate cancer progression and the novel development of an in vivo neuroendocrine model. J Urol. 2003; 169: 89. Abstract 346.
  • 17
    Busby JE,Shih SJ,Yang JC, et al. Angiogenesis is not mediated by prostate cancer neuropeptides. Angiogenesis. 2004; 6: 289293.
  • 18
    Rubenstein JH,Katin MJ,Mangano MM, et al. Small cell anaplastic carcinoma: 7 cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol. 1997; 20: 376380.
  • 19
    Leibovici D,Spiess PE,Agarwal PK, et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2006; 109: 198204.
  • 20
    Bunn PAJr,Carney DN. Overview of chemotherapy for small cell lung cancer. Semin Oncol. 1997; S7: 6974.
  • 21
    Psyrri A,Murren J. Small cell lung cancer: strategies to optimize chemotherapy response. Cancer J. 2001; S1: 2834.
  • 22
    Siefker-Radtke AO,Dinney CP,Abrahams NA, et al. Evidence supporting pre-operative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004; 172: 481484.
  • 23
    Siefker-Radtke AO,Kamat AM,Grossman HB, et al. Prospective evidence supporting the utility of neoadjuvant chemotherapy in small cell urothelial cancer: preliminary results from a phase II clinical trial at the M. D. Anderson Cancer Center. J Urol. 2006; 175: 399. Abstract 1240.